Bull, Bear & Beyond by Edison Group

Edison’s investment companies team recently published a review of The Diverse Income Trust. Managers Gervais Williams and Martin Turner believe that income stocks are set to become market leaders due to their steady cash returns to shareholders in an environment of nationalism and volatile asset prices. The UK looks particularly attractive as it has been devalued by persistent outflows since Brexi...

In this interview, Tom Pey (chairman and founder) and Celso Zuccollo (CEO) of Waymap, a privately held company, discuss their revolutionary indoor navigation platform. Originally developed with a $1m Google.org grant to assist visually impaired users, Waymap has evolved into a comprehensive platform operating across more than 11 cities and serving over 140 venues, including Washington Metro (over...

In this interview, we speak to Antti Vuolanto, CEO of Herantis Pharma. We discuss the company’s recently announced clinical data from its Phase Ib trial in Parkison's disease patients, what to expect from the upcoming biomarker data and the next steps for Herantis’s lead programme HER-096, a peptide therapeutic. **************************************************************************************...

In this interview, KEFI Gold and Copper’s chairman, Harry Anagnostaras-Adams discusses what lies in store for the company after closing $240m in senior project debt capital for its Tulu Kapi gold project in Ethiopia. He also covers why KEFI’s shares have been among the best performers in the sector, more than trebling from their level of 0.44p at the start of the year. ****************************...

In our interview, Card Factory’s CEO Darcy Willson-Rymer outlines the company’s progress reported in its H126 results, focusing on the performance of the stores, online activities and partnership businesses. He then gives some insight into the recently announced acquisition of funkypigeon.com, including what the acquisition provides to the group and the integration process. Darcy concludes with Ca...

In this interview, we speak with Jeppe Øvlesen, CEO, and Dr Thomas Jonassen, CSO of SynAct Pharma to discuss the company’s lead asset resomelagon, its unique mechanism of action and its broad applicability across inflammatory indications. Jeppe and Thomas also outline the ongoing Phase IIb trial, ADVANCE, evaluating resomelagon as a first-line treatment in rheumatoid arthritis in combination with...

In this interview, IP Group’s CEO, Greg Smith, highlights the potentially transformational implications of Pfizer’s acquisition of Metsera (for up to $7.3bn, of which $4.9bn is in upfront cash), whose MET-097 anti-obesity drug is progressing through Phase II. IP Group is entitled to low single‑digit royalties from a number of Metsera compounds, including MET‑097. EvaluatePharma forecasts that MET-...

In this interview, Silvia Comis MD, chief clinical and medical research officer at OSE Immunotherapeutics, covers the company’s lead immuno-oncology candidate, Tedopi. She outlines the current unmet need in non-small cell lung cancer, as well as Tedopi’s clinical track record to date. She also discusses the ongoing registrational Phase III ARTEMIA programme, alongside several other Phase II progra...

In this interview, Percheron Therapeutics CEO Dr James Garner discusses the company’s recent pivot to immuno-oncology and the rationale for licensing HMBD-002 as its lead programme. He outlines the potential of HMBD-002 as a novel VISTA-targeting checkpoint inhibitor, its differentiated positioning and the positive preclinical and clinical data reported to date. Dr Garner provides further insight...

In this interview, CEO David Veitch and CFO Adesh Kaul discuss Basilea Pharmaceutica’s strong H125 performance and the company’s key growth drivers. They outline the reasons for Cresemba’s continued strong momentum and Basilea’s strategy for growth beyond its lead asset’s maturity. They discuss Zevtera (recently launched in the US), fosmanogepix (on track for a new drug application filing in 2028)...

In this interview, Sonya Montgomery, chief development officer at OSE Immunotherapeutics, covers the company’s lead immuno-inflammation candidate, lusvertikimab. She outlines the current unmet need in the therapeutic areas of ulcerative colitis and inflammatory bowel disease, as well as lusvertikimab’s clinical track record to date. She also discusses potential next steps for the programme, includ...

In this video, we speak with Dr Tariq Mughal, chief medical officer at Mendus. We discuss Tariq’s interest in the blood cancer space before moving on to Mendus’s lead programme in acute myeloid leukaemia (AML) maintenance, as well as the potential to expand vididencel’s application to other indications. ************************************************************************************** About ‘B...

Edison’s investment companies team recently published a review on Templeton Emerging Markets Investment Trust (known as TEMIT). The trust’s two managers, Chetan Sehgal and Andrew Ness, have a straightforward investment strategy, focusing on companies with sustainable earnings power that are trading at a discount to their estimated intrinsic value. This approach has proved successful as TEMIT is ah...

In this interview, we speak to Carlos Buesa, CEO of Oryzon Genomics, with a focus on the company’s lead programme targeting agitation and aggression in borderline personality disorder (BPD) patients. Oryzon recently submitted the Phase III protocol to the FDA to initiate the PORTICO-2 trial, and regulatory clearance is expected in September 2025. Carlos discusses the progress of the BPD programme,...

In this interview, we speak with Concurrent’s CEO Miles Adcock and CFO Kim Garrod. Miles provides an overview of the business and explains the steps he has taken since joining the company in 2021. He discusses the performance of the Products business and the rationale for entering the Systems business, as well as the company’s approach to technology innovation. He closes with his view on potential...

In this interview, James Barham, CEO of PCI-PAL, provides an overview of the business and highlights from its recent trading update. He explains the rationale behind the updated three-year strategic plan, discussing PCI-PAL’s growth targets and planned investment to achieve them. He outlines the company’s approach to product development and its channel and direct sales strategies. He concludes by...

In this interview, Trisha Epp from Freelancer discusses the company’s recent selection by NASA as a supplier for its latest crowdsourcing multi-vendor panel. Trisha explains how the Freelancer platform can be used for crowdsourcing and discusses NASA’s use of crowdsourcing to seek solutions for complex technical challenges. She explains the history of Freelancer’s relationship with NASA and outlin...

In this interview, David Wolfin, president and CEO of Avino Silver & Gold Mines discusses the company's history and its growth prospects. Avino currently produces more than two million silver ounce equivalent per annum and has plans to quadruple its production capacity in the next five years. ************************************************************************************** About ‘Bull, Be...

Fresh from a major capital markets day, Foxtons Group CEO Guy Gittins sits down with Edison to discuss how the UK’s fastest-growing estate agency plans to double profits – again. From data-driven lettings expansion to AI-powered prospecting and high-margin acquisitions, this candid interview is a must-watch for anyone interested in property, growth strategy and the future of real estate. *********...

Edison’s investment companies team recently published a review on Franklin Global Trust (ticker: FRGT), which was formerly the Martin Currie Global Portfolio Trust. The Martin Currie brand will be retired and in July 2025, the trust’s manager, Zehrid Osmani and his team will join the much larger US-based Franklin Equity Group, whose CIO Jonathan Curtis will become co-manager of Franklin Global Tru...

In this interview, PWO Group CFO Jochen Lischer gives an overview of the company and comments on the main events and milestones in its recent transformation. He also discusses market dynamics, particularly the growth potential for lightweight engineering, as well as the competitive landscape. Lastly, Jochen talks about the group’s ambitions for the longer term. ************************************...

In this video, we speak with Stefan Weber, CEO of Newron Pharmaceuticals. We discuss the company’s registrational ENIGMA-TRS Phase III programme, the setting that evenamide is targeting and the licensing deals Newron has secured. Stefan also summarises the key milestones and catalysts that investors should watch out for across the next couple of years. *********************************************...

In this interview, Stephen Inglis, head of Regional REIT’s asset manager, ESR Europe LSPIM, and the de facto CEO of RGL, discusses in detail the prospects for the regional office market and the company’s strategy for delivering enhanced shareholder returns. The FY24 results published in March were in line with expectations and looking ahead, the outlook for the relative performance of regional off...

In this interview, Card Factory CEO Darcy Willson-Rymer provides an update on the progress the company is making on its ‘Opening Our New Future’ strategy following the publication of the FY25 results. Subjects covered include the developments in the company’s stores, online activities and partnerships. Darcy also discusses the company’s H2 weighting of profitability, the capital allocation policy...

Edison recently published a note on Gresham House Energy Storage Fund, known by its ticker, GRID. GRID is the largest owner and operator of battery energy storage systems in the UK. Its operational portfolio represents 17% of the market in megawatt terms. This is more than twice the market share of its nearest competitor. GRID’s annual results for the year ended December 2024 confirm that after a...